Cargando…
New risk score for predicting progression of membranous nephropathy
BACKGROUND: Patients with Idiopathic membranous nephropathy (IMN) have various outcomes. The aim of this study is to construct a tool for clinicians to precisely predict outcome of IMN. METHODS: IMN patients diagnosed by renal biopsy from Shanghai Ruijin Hospital from 2009.01 to 2013.12 were enrolle...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368730/ https://www.ncbi.nlm.nih.gov/pubmed/30736804 http://dx.doi.org/10.1186/s12967-019-1792-8 |
_version_ | 1783394047575982080 |
---|---|
author | Xiaofan, Hu Jing, Xu Chenni, Gao Yifan, Wu Xialian, Yu Li, Lin Hong, Ren Wen, Zhang Weiming, Wang Xiaoxia, Pan Jingyuan, Xie Nan, Chen |
author_facet | Xiaofan, Hu Jing, Xu Chenni, Gao Yifan, Wu Xialian, Yu Li, Lin Hong, Ren Wen, Zhang Weiming, Wang Xiaoxia, Pan Jingyuan, Xie Nan, Chen |
author_sort | Xiaofan, Hu |
collection | PubMed |
description | BACKGROUND: Patients with Idiopathic membranous nephropathy (IMN) have various outcomes. The aim of this study is to construct a tool for clinicians to precisely predict outcome of IMN. METHODS: IMN patients diagnosed by renal biopsy from Shanghai Ruijin Hospital from 2009.01 to 2013.12 were enrolled in this study. Primary outcome was defined as a combination of renal function progression [defined as a reduction of estimated glomerular filtration rate (eGFR) equal to or over 30% comparing to baseline], ESRD or death. Risk models were established by Cox proportional hazard regression analysis and validated by bootstrap resampling analysis. ROC curve was applied to test the performance of risk score. RESULTS: Totally 439 patients were recruited in this study. The median follow-up time was 38.73 ± 19.35 months. The enrolled patients were 56 (15–83) years old with a male predominance (sex ratio: male vs female, 1:0.91). The median baseline serum albumin, eGFR-EPI and proteinuria were 23(8–43) g/l, 100.31(12.81–155.98) ml/min/1.73 m(2) and 3.98(1.50–22.98) g/24 h, respectively. In total, there were 36 primary outcomes occurred. By Cox regression analysis, the best risk model included age [HR: 1.04(1.003–1.08), 95% CI from bootstrapping: 1.01–1.08), eGFR [HR: 0.97 (0.96–0.99), 95% CI from bootstrapping: 0.96–0.99) and proteinuria [HR: 1.09 (1.01–1.18), 95% CI from bootstrapping: 1.02–1.16). One unit increasing of the risk score based on the best model was associated with 2.57 (1.97–3.36) fold increased risk of combined outcome. The discrimination of this risk score was excellent in predicting combined outcome [C statistics: 0.83, 95% CI 0.76–0.90]. CONCLUSIONS: Our study indicated that older IMN patients with lower eGFR and heavier proteinuria at the time of renal biopsy were at a higher risk for adverse outcomes. A risk score based on these three variables provides clinicians with an effective tool for risk stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-019-1792-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6368730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63687302019-02-15 New risk score for predicting progression of membranous nephropathy Xiaofan, Hu Jing, Xu Chenni, Gao Yifan, Wu Xialian, Yu Li, Lin Hong, Ren Wen, Zhang Weiming, Wang Xiaoxia, Pan Jingyuan, Xie Nan, Chen J Transl Med Research BACKGROUND: Patients with Idiopathic membranous nephropathy (IMN) have various outcomes. The aim of this study is to construct a tool for clinicians to precisely predict outcome of IMN. METHODS: IMN patients diagnosed by renal biopsy from Shanghai Ruijin Hospital from 2009.01 to 2013.12 were enrolled in this study. Primary outcome was defined as a combination of renal function progression [defined as a reduction of estimated glomerular filtration rate (eGFR) equal to or over 30% comparing to baseline], ESRD or death. Risk models were established by Cox proportional hazard regression analysis and validated by bootstrap resampling analysis. ROC curve was applied to test the performance of risk score. RESULTS: Totally 439 patients were recruited in this study. The median follow-up time was 38.73 ± 19.35 months. The enrolled patients were 56 (15–83) years old with a male predominance (sex ratio: male vs female, 1:0.91). The median baseline serum albumin, eGFR-EPI and proteinuria were 23(8–43) g/l, 100.31(12.81–155.98) ml/min/1.73 m(2) and 3.98(1.50–22.98) g/24 h, respectively. In total, there were 36 primary outcomes occurred. By Cox regression analysis, the best risk model included age [HR: 1.04(1.003–1.08), 95% CI from bootstrapping: 1.01–1.08), eGFR [HR: 0.97 (0.96–0.99), 95% CI from bootstrapping: 0.96–0.99) and proteinuria [HR: 1.09 (1.01–1.18), 95% CI from bootstrapping: 1.02–1.16). One unit increasing of the risk score based on the best model was associated with 2.57 (1.97–3.36) fold increased risk of combined outcome. The discrimination of this risk score was excellent in predicting combined outcome [C statistics: 0.83, 95% CI 0.76–0.90]. CONCLUSIONS: Our study indicated that older IMN patients with lower eGFR and heavier proteinuria at the time of renal biopsy were at a higher risk for adverse outcomes. A risk score based on these three variables provides clinicians with an effective tool for risk stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-019-1792-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-02-08 /pmc/articles/PMC6368730/ /pubmed/30736804 http://dx.doi.org/10.1186/s12967-019-1792-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Xiaofan, Hu Jing, Xu Chenni, Gao Yifan, Wu Xialian, Yu Li, Lin Hong, Ren Wen, Zhang Weiming, Wang Xiaoxia, Pan Jingyuan, Xie Nan, Chen New risk score for predicting progression of membranous nephropathy |
title | New risk score for predicting progression of membranous nephropathy |
title_full | New risk score for predicting progression of membranous nephropathy |
title_fullStr | New risk score for predicting progression of membranous nephropathy |
title_full_unstemmed | New risk score for predicting progression of membranous nephropathy |
title_short | New risk score for predicting progression of membranous nephropathy |
title_sort | new risk score for predicting progression of membranous nephropathy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368730/ https://www.ncbi.nlm.nih.gov/pubmed/30736804 http://dx.doi.org/10.1186/s12967-019-1792-8 |
work_keys_str_mv | AT xiaofanhu newriskscoreforpredictingprogressionofmembranousnephropathy AT jingxu newriskscoreforpredictingprogressionofmembranousnephropathy AT chennigao newriskscoreforpredictingprogressionofmembranousnephropathy AT yifanwu newriskscoreforpredictingprogressionofmembranousnephropathy AT xialianyu newriskscoreforpredictingprogressionofmembranousnephropathy AT lilin newriskscoreforpredictingprogressionofmembranousnephropathy AT hongren newriskscoreforpredictingprogressionofmembranousnephropathy AT wenzhang newriskscoreforpredictingprogressionofmembranousnephropathy AT weimingwang newriskscoreforpredictingprogressionofmembranousnephropathy AT xiaoxiapan newriskscoreforpredictingprogressionofmembranousnephropathy AT jingyuanxie newriskscoreforpredictingprogressionofmembranousnephropathy AT nanchen newriskscoreforpredictingprogressionofmembranousnephropathy |